ITOS iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.

$35.32  +0.86 (2.50%)
As of 11/30/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/24/2020
Outstanding shares:  35,273,893
Average volume:  263,910
Market cap:   $1,239,524,600
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    46565G104
ISIN:        US46565G1040
Sedol:      BMWXFT4
Valuation   (See tab for details)
PE ratio:   17.45
PB ratio:   3.27
PS ratio:   11.89
Return on equity:   3.96%
Net income %:   14.14%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy